FORT WORTH, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative ...

TFF Pharmaceuticals’ proprietary Thin Film Freezing (TFF) technology allows for the transformation of both existing compounds and new chemical entities into dry powder formulations exhibiting unique ...

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company focused on developing and commercializing new inhalation drug products for the treatment of chronic ...

The call will also be broadcast live over the Web and can be accessed on TFF Pharmaceuticals’ Website, https://tffpharma.com or directly at https://viavid.webcasts ...

New Gene Expression Analysis from Ongoing Phase 2 Study Provides Strong Biomarker Evidence that Treatment with TFF TAC Results in Normalization of Rejection-Related Genes TFF TAC Prevented Rejection ...

FORT WORTH, Texas, Jan. 09, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug ...

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its ...

TangenX Technology Corporation is a manufacturer of tangential flow filtration (TFF) products for use in applications in the biopharmaceutical industry, including our market-leading Sius™ Single Use ...

In this presentation we presented an innovative integrated system designed to automate the tangential flow filtration (TFF) process based on inline concentration measurement. This system employs ...

Presentation will feature initial data from the Company’s ongoing Phase 2 study of Tacrolimus Inhalation Powder (TFF TAC), which is being developed to prevent lung transplant rejection FORT WORTH, ...